Syra Health Corp. Class A Common Stock Q4 FY2023 earnings call

Management Statement and Operational Highlights

• 2023 was transformational with successful IPO and trading on NASDAQ.
• Expanded customer geography from Indiana to 17 states.
• Diversified revenues beyond legacy healthcare workforce to digital health, population health, and health education; non-healthcare workforce business units grew 250% in 2023, accounting for 23% of total revenues vs 6% in 2022.
• Launched Syrenity, SyraBot, and CarePlus on the technology front.
• Strengthened balance sheet to support growth objectives.
• 2024 outlook: Expect revenues to be $9 million to $11 million, 64%-100% growth from 2023, driven by population health, healthcare workforce, behavioral & mental health, digital health, and health education; expanded into federal government space with new government solutions business unit.

Segment Performance

• Population Health: Grew more than 125% in 2023, with revenues of $716,000 versus $318,000 in 2022. Driven by demand for epidemiology services.
• Healthcare Workforce: Revenues were $4.3 million in 2023 versus $5.3 million in 2022. Decline due to subsiding of COVID-19 pandemic. Based on contracts on hand, expected to resume strong growth in 2024.
• Digital Health: Revenues for full year 2023 were $515,000, starting to generate revenues in Q3 2023 with sales of SyraBot. Launched CarePlus in 2023.
• Behavioral & Mental Health and Health Education: Combined revenues were $25,000 in 2023 versus $39,000 in 2022.
• Gross Margins: Full year 2023 gross margins were 25.6%, a 670 basis point increase versus 2022, due to shift to higher margin services like population health and digital health.

Guidance

• 2024 revenues expected in the range of $9 million to $11 million, representing 64% to 100% growth versus 2023.
• Guidance does not include potential revenues from Caduceus Healthcare's Federal Influx Care Facilities contract.
• Expect strong growth in 2024 from population health and healthcare workforce business units, coupled with growth from behavioral & mental health, digital health, and health education business units.

Risks

• No specific risks explicitly discussed in the transcript.

Q: With regards to your outlook of $9 million to $11 million in 2024, what is your visibility into those numbers? And is there upside to these estimates?

A: Yes, we see upside in these estimates as the press release mentions. These numbers do not include revenue from the Caduceus Healthcare contract, which we are anticipating, and don't constitute revenue from other federal government contracts we may win yet this year.

Q: You recently announced that you're a subcontractor of Caduceus Healthcare with regards to the Federal Influx program, it's worth about $75 billion. Can you provide some details on this contract in terms of the timing and your expectations?

A: Syra Health announced a partnership with Caduceus Healthcare, where Syra Health will serve as a subcontractor to Caduceus, the prime contractor for the award from the Federal Department of Health and Human Services. Syra Health anticipates involvement in the contract from our healthcare workforce, mental and behavioral health, and health education business units in support of the Federal Influx Care Facilities which provides care for unaccompanied migrant children. Syra Health expects to win task orders from the contract and announce them as they are received.

Q: The growth in population health has been really strong. What is driving that business unit?

A: There has been increasing demand for our population health services driven by our epidemiology and health equity services. We have a talented team of expert epidemiologists and research scientists who are performing data collection and analysis and program evaluations in order to help improve the health of specific communities or entire populations.